Immunological selection of tumour cells which have lost SV40 antigen expression

Nature ◽  
1977 ◽  
Vol 269 (5623) ◽  
pp. 36-40 ◽  
Author(s):  
P. T. Mora ◽  
C. Chang ◽  
L. Couvillion ◽  
J. M. Kuster ◽  
V. W. McFarland
1979 ◽  
Vol 9 (1) ◽  
pp. 465-475 ◽  
Author(s):  
Tina Dalianis ◽  
George Klein ◽  
Birger Andersson

Small GTPases ◽  
2020 ◽  
pp. 1-17
Author(s):  
Dominika a Rudzka ◽  
Susan Mason ◽  
Matthew Neilson ◽  
Lynn McGarry ◽  
Gabriela Kalna ◽  
...  

2009 ◽  
Vol 41 (6) ◽  
pp. 1421-1429 ◽  
Author(s):  
Ester Martín-Villar ◽  
María M. Yurrita ◽  
Beatriz Fernández-Muñoz ◽  
Miguel Quintanilla ◽  
Jaime Renart

2013 ◽  
Vol 33 (6) ◽  
Author(s):  
Nívea Dias Amoêdo ◽  
Juan Perez Valencia ◽  
Mariana Figueiredo Rodrigues ◽  
Antonio Galina ◽  
Franklin David Rumjanek

Tumour cells thrive in environments that would be hostile to their normal cell counterparts. Survival depends on the selection of cell lines that harbour modifications of both, gene regulation that shifts the balance between the cell cycle and apoptosis and those that involve the plasticity of the metabolic machinery. With regards to metabolism, the selected phenotypes usually display enhanced anaerobic glycolysis even in the presence of oxygen, the so-called Warburg effect, and anabolic pathways that provide precursors for the synthesis of lipids, proteins and DNA. The review will discuss the original ideas of Otto Warburg and how they initially led to the notion that mitochondria of tumour cells were dysfunctional. Data will be presented to show that not only the organelles are viable and respiring, but that they are key players in tumorigenesis and metastasis. Likewise, interconnecting pathways that stand out in the tumour phenotype and that require intact mitochondria such as glutaminolysis will be addressed. Furthermore, comments will be made as to how the peculiarities of the biochemistry of tumour cells renders them amenable to new forms of treatment by highlighting possible targets for inhibitors. In this respect, a case study describing the effect of a metabolite analogue, the alkylating agent 3BP (3-bromopyruvate), on glycolytic enzyme targets will be presented.


1989 ◽  
Vol 170 (6) ◽  
pp. 2177-2182 ◽  
Author(s):  
C M Roifman ◽  
D Hummel ◽  
H Martinez-Valdez ◽  
P Thorner ◽  
P J Doherty ◽  
...  

CD8 molecules expressed on the surface of a subset of T cells participate in the selection of class I MHC antigen-restricted T cells in the thymus, and in MHC-restricted immune responses of mature class I MHC antigen-restricted T cells. Here we describe an immune-deficient patient with lack of CD8+ peripheral blood cells. The patient presented with Pneumocystis carinii pneumonia and was unable to reject an allogeneic skin graft, but had normal primary and secondary antibody responses. Examination of the patient's thymus revealed that the loss of CD8+ cells occurred during intrathymic differentiation: the patient's immature cortical thymocytes included both CD4+ and CD8+ cells while the mature medullary cells expressed the CD4 but not the CD8 protein on their surface. Northern blot and polymerase chain reaction analyses revealed the presence of CD8 alpha and beta mRNA in the patient's thymus but not in the peripheral blood. Both class I MHC antigen expression and the expressed TCR V beta repertoire are normal in this patient. These data are consistent with an impaired selection of CD8+ cells in the patient's thymus and support the role of the CD8 surface protein in thymic selection previously characterized in genetically manipulated and inbred mice.


2019 ◽  
Vol 121 (11) ◽  
pp. 979-982 ◽  
Author(s):  
Giosue Scognamiglio ◽  
Annarosaria De Chiara ◽  
Antonina Parafioriti ◽  
Elisabetta Armiraglio ◽  
Flavio Fazioli ◽  
...  

Abstract Selection of cancer patients for treatment with immune checkpoint inhibitors remains a challenge due to tumour heterogeneity and variable biomarker detection. PD-L1 expression in 24 surgical chordoma specimen was determined immunohistochemically with antibodies 28-8 and E1L3N. The ability of patient-derived organoids to detect treatment effects of nivolumab was explored by quantitative and qualitative immunofluorescence and FACS analysis. The more sensitive antibody, E1L3N (ROC = 0.896, p = 0.001), was associated with greater tumour diameters (p = 0.014) and detected both tumour cells and infiltrating lymphocytes in 54% of patients, but only 1–15% of their cells. Organoids generated from PD-L1-positive patients contained both tumour cells and PD-1/CD8-positive lymphocytes and responded to nivolumab treatment with marked dose-dependent diameter reductions of up to 50% and increased cell death in both PD-L1-positive and negative organoids. Patient-derived organoids may be valuable to predict individual responses to immunotherapy even in patients with low or no immunohistochemical PD-L1 expression.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Abdirahman I. Abdi ◽  
George M. Warimwe ◽  
Michelle K. Muthui ◽  
Cheryl A. Kivisi ◽  
Esther W. Kiragu ◽  
...  

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 418-418
Author(s):  
Richard Walshaw ◽  
Jamie Honeychurch ◽  
Joanne Roberts ◽  
Jacqueline Swan ◽  
Laura Dean ◽  
...  

418 Background: Many patients with bladder cancer (BC) undergo radiotherapy (RT) during the course of their treatment. There is emerging evidence that RT can cause immune stimulatory changes within the tumour microenvironment (TME), potentially contributing to its efficacy. We aimed to determine if RT induces immunogenic changes in murine BC cell lines, and develop a pre-clinical model of BC with a TME reflective of de novo tumours in order to test this premise in vivo. Methods: Immunogenic effects of RT were determined using murine vaccination studies with irradiated tumour cells. RT-induced immuno-phenotypic changes in surface antigen expression on tumour cells were ascertained using flow cytometry. An orthotopic BC model was established using MBT2 cells instilled intravesically in C3H/Hen mice, and resulting tumours monitored with ultrasound (US). We used immunohistochemical (IHC) staining to determine the immune contexture of the TME within developing orthotopic tumours. Results: C57BL/6 mice inoculated with irradiated MB49 cells demonstrated improved survival compared to control mice after subsequent rechallenge with viable tumour cells. This effect was not seen in C3H mice implanted with irradiated MBT2 cells. RT led to upregulation of immune stimulatory molecules CD80, MHC I, and Fas on MB49 but not MBT2 cells. Tumours developed in 80% of mice following catheter implant, and visible on US 3-4 weeks after instillation. Profiling of the TME with IHC demonstrated that tumours contained few CD8+ T-cells, but high numbers of myeloid cells. Conclusions: RT induces immune stimulatory effects on murine BC cells, including upregulation of several surface proteins. In future work, we will determine the effects of RT on the TME in the orthotopic model, and correlate these with the expression of various immunogenic cell surface proteins. This may lead to the discovery of a biomarker to predict which patients with BC would benefit from combination of an immunomodulatory agent with RT.


Sign in / Sign up

Export Citation Format

Share Document